Epidermolysis bullosa dystrophica

Signs and symptoms

The deficiency in anchoring fibrils impairs the adherence between the epidermis and the underlying dermis. This deficiency occurs due to the genetic mutation(s) in the COL7A1 gene in chromosome 3. The COL7A1 gene in chromosome 3 is responsible for coding for type VII collagen, a protein that assists in helping anchor the epidermis and dermis. Thus, the skin of DEB patients is highly susceptible to mild to severe blistering, depending on the subtype. Collagen VII is also associated with the epithelium of the esophageal lining, and DEB patients may have chronic scarring, webbing, and obstruction of the esophagus. Affected individuals are often severely malnourished due to trauma to the oral and esophageal mucosa and require feeding tubes for nutrition. They also have iron-deficiency anemia of uncertain origin, which leads to chronic fatigue.

Open wounds on the skin heal slowly or not at all, often scarring extensively, and are particularly susceptible to infection. Many individuals bathe in a bleach and water mixture to fight off these infections. The chronic inflammation leads to errors in the DNA of the affected skin cells, which in turn causes squamous cell carcinoma (SCC). The majority of these patients die before the age of 30, either of SCC or complications related to DEB.

The chronic inflammatory state seen in recessive dystrophic epidermolysis bullosa (RDEB) may cause small fiber peripheral neuropathy (SFN). RDEB patients have reported the sensation of pain in line with neuropathic pain qualities.

Causes

DEB is caused by genetic defects (or mutations) within the human COL7A1 gene encoding the protein type VII collagen (collagen VII). DEB-causing mutations can be either dominant or recessive. Most families with family members with this condition have distinct mutations.

Collagen VII is a very large molecule (300 kDa) that dimerizes to form a semicircular looping structure: the anchoring fibril. Anchoring fibrils are thought to form a structural link between the epidermal basement membrane and the fibrillar collagens in the upper dermis.

Pathophysiology

In the absence of mutations of the COL7A1 gene, an autoimmune response against type VII collagen can result in an acquired form of epidermolysis bullosa called epidermolysis bullosa acquisita.

There exist other types of inherited epidermolysis bullosa, junctional epidermolysis bullosa and epidermolysis bullosa simplex, which are not related to type VII collagen deficiency. These arise from mutations in the genes encoding other proteins of the epidermis or the basement membrane at the junction between the epidermis and the dermis.

Diagnosis

Classification

Treatment

In May 2023, the US Food and Drug Administration (FDA) approved Vyjuvek for the treatment of wounds in people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

Birch triterpenes

References

Sources

References

1. Reference, Genetics Home. "dystrophic epidermolysis bullosa".
2. (24 September 2020). "Epidermolysis bullosa". Nature Reviews Disease Primers.
3. Pittman, Taylor. (21 April 2015). "'Butterfly Child' With Rare, Painful Condition Displays Strength That Will Blow You Away". Huffington Post.
4. "Dystrophic epidermolysis bullosa".
5. [https://www.ncbi.nlm.nih.gov/pubmed/?term=painful+small+fibre+neuropathy+recessive+dystrophic], Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy.
6. Schräder NHB, Yuen WY, Jonkman MF. (2018). "Pain Quality Assessment Scale for Epidermolysis Bullosa". Acta Derm Venereol.
7. (March 2007). "Epidermolysis bullosa. II. Type VII collagen mutations and phenotype–genotype correlations in the dystrophic subtypes". [[Journal of Medical Genetics]].
8. Pfendner, Ellen G.. (2018-09-13). "Dystrophic Epidermolysis Bullosa". University of Washington, Seattle.
9. (May 2005). "High frequency of the 425A→G splice-site mutation and novel mutations of the ''COL7A1'' gene in central Europe: significance for future mutation detection strategies in dystrophic epidermolysis bullosa". [[British Journal of Dermatology]].
10. (May–June 2007). "Immunopathology and molecular diagnosis of autoimmune bullous diseases". [[Journal of Cellular and Molecular Medicine]].
11. (2008). "The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB". [[Journal of the American Academy of Dermatology]].
12. {{harvnb. James. Berger. Elston. 2005
13. {{harvnb. Freedberg. Eisen. Wolff. Austen. 2003
14. {{harvnb. Freedberg. Eisen. Wolff. Austen. 2003
15. {{harvnb. Rapini. Bolognia. Jorizzo. 2007
16. {{harvnb. James. Berger. Elston. 2005
17. Commissioner, Office of the. (19 May 2023). "FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa".
18. (19 May 2023). "Vyjuvek".